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resumo 
 
 
O metotrexato é um agente quimioterápico usado para tratar uma variedade de 
cancros. No entanto, a ocorrência de resistência limita a sua eficácia. A 
relação entre o estado redox do citocromo c, apoptose e o desenvolvimento de 
resistência ao metotrexato foi avaliada em células humanas de cancro da 
mama. O citocromo c no seu estado reduzido é menos capaz de induzir a 
cascata apoptótica. Aqui nós mostramos que células incubadas com agentes 
redutores de citocromo c, tais como tetrametilfenildiamina, ascorbato ou 
glutationa reduzida, demonstraram menos mortalidade e apoptose na 
presença do metotrexato. Por outro lado, a inibição de glutationa aumentou a 
acção apoptótica do metotrexato, demonstrando um envolvimento do estado 
redox do citocromo c na apoptose induzida por metotrexato. Usando 
ferramentas de genómica funcional detectámos que GSTM1 e GSTM4 foram 
sobreexpressos em células MCF7 resistentes ao metotrexato. A inibição 
destas isoformas causou um aumento na citotoxicidade em células sensíveis. 
Estes resultados sugerem que estas GSTs específicas juntamente com a 
glutationa reduzida endógena poderão ajudar a manter o citocromo c num 
estado mais reduzido o que por sua vez poderá causar uma diminuição na 
apoptose e contribuindo assim para a resistência ao metotrexato em células 
tumorais humanas. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
keywords 
 
cytochrome c; redox state; methotrexate resistance; apoptosis; GSTs; 
GSH; breast cancer 
abstract 
 
Methotrexate is a chemotherapeutic agent used to treat a variety of cancers. 
However, the occurrence of resistance limits its effectiveness. The relationship 
among redox-state of cytochrome c, apoptosis and development of resistance 
to methotrexate was assessed in human breast cancer cells. Cytochrome c in 
its reduced state is less capable of triggering the apoptotic cascade. Here we 
show that cells incubated with cytochrome c-reducer agents, such as 
tetramethylphenylenediamine, ascorbate or reduced glutathione, showed less 
mortality and apoptosis in the presence of methotrexate. Conversely, depletion 
of glutathione increased the apoptotic action of methotrexate, demonstrating an 
involvement of cytochrome c redox state in methotrexate-induced apoptosis. 
Using functional genomics we detected that GSTM1 and GSTM4 were 
overexpressed in methotrexate-resistant MCF7 breast cancer cells. Inhibition of 
these isoforms caused an increase in methotrexate cytotoxicity in sensitive 
cells. These results suggest that these specific GSTs together with 
endogenous reduced glutathione would help to maintain a more reduced state 
of cytochrome c which in turn would cause a decrease in apoptosis thus 
contributing to methotrexate resistance in human cancer cells. 
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1. Methotrexate and cancer treatment 
 
1.1. Mechanism of action: cell cycle S phase arrest and apoptosis 
 
Methotrexate (MTX) is an antifolate chemotherapeutic agent widely used, 
alone or in combination with other agents for the treatment of a range of cancers, 
such as breast cancer, osteosarcoma, head and neck cancer, lymphoma and acute 
lymphoblastic leukemia (Jolivet et al. 1983).  
This type of drug and its polyglutamates inhibit competitively and reversely 
the dihydrofolate reductase (DHFR) affecting the synthesis de novo of purines and 
pirimidines, thus the treatment with MTX results in the DNA synthesis inhibition, 
causing p53 mediated cell cycle arrest in S phase and death cell generally by 
triggering apoptosis in several cell lines (Kaufmann 1989; Barry et al. 1990; da 
Silva et al. 1996; el Alaoui et al. 1997; Hattangadi et al. 2004). The absence of 
folates and nucleotides precursors causes changes in the DNA synthesis, once the 
carbon atoms exchange reactions are blocked. In this case, following the DNA 
damage caused by this type of anticancer drug, apoptosis may occur as a major 
event, where apoptotic regulating genes will influence the lethal effect of this drug 
or may be a secondary response to the induced drug cytotoxic effect (Brown and 
Wouters 1999; Tannock and Lee 2001). Tumor cells which proliferate abnormally 
are particularly susceptible to the lethal effects of the MTX.  
 
DHFR catalyzes the reduction of dihydrofolate (DHF) to tetrahydrofolate 
(THF) which is necessary, as well as its derivatives, as cofactor in different 
biochemical mechanisms involved in carbonyl groups transference, such as 
aminoacids (e.g. methionine) and the purines and pyrimidines synthesis as well. 
Thus, DHFR is a very important enzyme in the DNA replication and cell division, by 
keeping the intracellular reduced folate levels. Also thymidylate synthase (TS) has 
an important role in DNA synthesis, since it catalyzes thymidine monophosphate 
formation (dTMP) from deoxyuridine monophosphate (dUMP), precursor of 
pyrimidines. 
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Figure 1– Schematic representation of folates (F) metabolism. Reduction of 
dihydrofolate (DHF) to tetrahydrofolate (THF) catalyzed by dihydrofolate 
reductase (DHFR). THF.C1 represents THF active derivatives that participate in 
specific folate-dependent reactions. (Adapted and modified from unknown source) 
 
The natural folates are formed by three structural components: a ptheridin 
ring, an acid p-aminobenzoic and a glutamate (Figure 2a). The antifolates also 
share this structure however with slight variations (Figure 2b). 
 
  a 
 
 
 
 
 
 
  b 
 
 
 
 
Figura 2– Chemical structure of natural folates (a) and methotrexate 
(antifolate) (b). 
pteridine ring  p-aminobenzoic acid  glutamyl residues  
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1.1. Mechanisms of MTX resistance 
 
The occurrence of resistance to MTX upon treatment compromises its 
effectiveness, limiting its use in chemotherapy (Hryniuk and Bertino 1969) and its 
occurrence can be either by a single mechanism or by combination of several of 
them (Sharma et al. 1991), thus drug resistance is a complex process in which 
several pathways can be involved. Several resistance mechanisms in vitro have 
been described using mammalian cells as model. Following, a brief description of 
each mechanism: 
 
1.2.1. Gene amplification of the DHFR locus 
 
One explanation for the amplification of the DHFR gene copy number could 
be due to unequal sister chromatid exchanges generating stable chromossomic 
regions. It has also been described that the generation of extrachromossomic 
copies of the DHFR gene, normally lost in daughter cells because of the absence of 
the centromere, is associated to the amplification process (Schimke et al., 1981). 
Other studies suggested a direct relationship between the amplication of the DHFR 
gene and mutated p53 gene (Livingstone et al. 1992). 
 
1.2.2. Deficiency in MTX transport 
 
MTX transport into the cell occurs mainly through a specific folate/antifolate 
transporter named reduced folate carrier (RFC). RFC is a membrane glycoprotein 
encoded by SLC19A1 gene. Underexpression of human SLC19A1 gene seems to be 
the central mechanism associated to the deficiency in MTX transport (Gorlick et al. 
1997; Belkov et al. 1999; Guo et al. 1999; Ferreri et al. 2004) probably caused by 
the loss or deletion of locus SLC19A1 (Ding et al. 2001; Zhao et al. 2004). Another 
common mechanism associated to resistance development is the occurrence of 
SLC19A1 gene mutations, changing the transporter function, thus causing a 
decrease in MTX transport and originating the drug resistance (Roy et al. 1998; 
Rothem et al. 2002). 
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1.2.3. Reduction in the MTX polyglutamation 
 
Polyglutamation is a biochemical process with an important role in the MTX 
pharmacology (Rosowsky et al. 1982). Like for the natural folates, folil 
polyglutamate synthase (FPGS) has high affinity to MTX adding sequentially five 
groups of glutamate to its molecule. Once it has more than three glutamate groups, 
MTX is no longer substrate for the RFC transport system, causing the accumulation 
of polyglutamated MTX inside the cell (Cowan and Jolivet 1984). This 
polyglutamated form of MTX is further a stronger inhibitor of the synthesis of 
purines and pyrimidines (Kimura et al. 2004) by DHFR and other THF-dependent 
enzymes inhibition (Cheok and Evans 2006). This inhibition can still remain even 
after the chemotherapeutic treatment, increasing the cytotoxic activity of the MTX 
(Cowan and Jolivet 1984). 
The occurrence of less polyglutamation had been described in resistant cells 
(McCloskey et al. 1991; Mauritz et al. 2002; Liani et al. 2003). It is already 
described that several tumor cell lines resistant to antifolates show a suppression 
in the FPGS activity, probably due to post-translational alterations or gene 
mutations (Roy et al. 1997), thus the decrease in the accumulation of 
polyglutamated MTX can be associated to a low activity of FPGS. 
 
1.2.4. Increase of the multi-drug resistance phenotype 
 
The development of drug resistance in chemotherapy has been related to 
several mechanisms and it may occur as a multifactorial event where several 
mechanisms are simultaneously activated. The appearance of the multi-drug 
resistance (MDR) phenotype is a great concern regarding the chemotherapeutic 
treatment in several types of cancer (Sharom 1997). This phenotype can be 
inherited, an innate property of tumor cells, or acquired upon drug treatment 
(Sharom 1997). Its development can be associated to classic mechanisms, directly 
involved in DNA replication or detoxification processes: 1) the classic MDR 
phenotype can result from the overexpression of the p-glycoprotein, encoded by 
mdr1 gene, and from other multidrug resistance proteins (MRP) involved in the 
decrease of intracellular drug concentration through its ATP-dependent efflux. The 
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p-glycoprotein is an ATP-dependent translocase known for its ability to carry 
chemotherapeutic drugs, such as MTX (Sharom 1997); 2) the development of non-
classic MDR phenotype is normally associated to alterations in the levels or activity 
of topoisomerase II and overexpression of detoxification enzymes phase II such as 
glutathione S-transferases (GSTs), UDP-glucuronosyl transferases (UGTs), 
aldehyde dehydrogenases (ALDHs) and aldo-keto reductases (AKRs) (Ax, 2000; 
Inoue, 1993). However, this type of MDR phenotype could be masked by the 
activation of the drug efflux via MDR or MDP. 
Hereupon, it has been supposed that the increase of the MDR phenotype 
could be associated to alterations in the functional p-glycoprotein caused by the 
exposure to high doses of MTX (Assaraf et al. 1989). It is also described that the 
overexpression of different members of MRP family provides resistance to 
antifolates, although it is not described MRP overexpression in antifolate selected 
cell lines (Assaraf 2007). 
 
1.2.5. Mutations of the DHFR gene 
 
Mutations in DHFR gene in resistant cell lines decrease the affinity of DHFR 
protein to MTX compromising its inhibition by this drug, thus favoring the 
occurrence of the resistance (Srimatkandada et al. 1989). 
 
1.2.6. Altered genes 
 
Besides DHFR gene, other genes have been identified also important in the 
development of the MTX resistant phenotype, such as AKR1C1, UGT1A6, DKK1, E-
cadherin, caveolin 1, enolase-2, PRKCA, EEF1A1 and S100A4. 
 
1.2.6.1. Overexpression of AKR1C1 
 
Aldo-keto reductase (AKR) superfamily proteins are monomeric 
cytoplasmic proteins and have been suggested to be involved in detoxification 
processes (Maser 1995; Burczynski et al. 1999; O'Connor et al. 1999; Penning 
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2005) by catalyzing the NAD(P)H-dependent oxido-reduction of a variety of 
substrates (Jez et al. 1997). 
Overexpression of AKR1C1 has been related to drug resistance in a range of 
cancers. Some anticancer drugs share similar chemical structure with some 
compounds metabolized by AKR1C1, suggesting that these drugs may be subject to 
this enzyme activity (Hsu et al. 2001). Several studies using different anti-cancer 
drugs are in concordance with this, altogether suggesting an association between 
AKR1C1 and drug detoxification (Ciaccio et al. 1993; Shen et al. 1997; Ax et al. 
2000; Deng et al. 2004; Chen et al. 2005; Hung et al. 2006). Also MTX-resistant 
colon cancer cells showed an overexpression of AKR1C1 (Selga et al. 2008). In this 
study, AKR1C1 overexpression seems to represent a mechanism, parallel to DHFR 
amplification, to the development of MTX resistance, once AKR1C1 up-regulation 
counteracted MTX-induced S phase arrest of cell cycle and apoptosis caused by the 
drug. 
 
1.2.6.2. Overexpression of S100A4 
 
S100A4 belongs to the S100 calcium binding protein family and as many 
members of this family, S100A4 is a symmetric homodimer characterized by the 
presence of two calcium binding sites of EF-hand type (helix-loop-helix) 
(Dukhanina et al. 1997) that allow S100 proteins to respond to calcium stimulus 
induced by cell signaling. It has been involved in the regulation of a wide variety of 
cellular processes, such as protein phosphorylation, dynamics of cytoskeleton 
constituents or Ca2+ homeostasis (Donato 2001; Donato 2003). S100A4 has been 
described to have a function in cell cycle progression, in cell motility and as 
modulator of intracellular adhesion and of the invasive properties of cells (Sherbet 
and Lakshmi 1998; Donato 2001). Its overexpression has been associated to tumor 
malignancy (Parker et al. 1994), metastasis (Lloyd et al. 1998), angiogenesis 
(Ambartsumian et al. 2001) and drug resistance as well (Mahon et al. 2007).  
Mencia et al. (2010) demonstrated that S100A1 is overexpressed in several 
MTX-resistant colon cancer, breast cancer, pancreatic cancer, leukemia and 
osteosarcoma cell lines. This study also showed that cellular knockdown of S100A4 
in parental cells leads to chemosensitization toward MTX and overexpression 
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desensitizes the cells toward this drug, suggesting a role for S100A1 in MTX-
resistance in colon cancer cells.  
 
1.2.6.3. Overexpression of caveolin-1, enolase-2 and PRKCA 
and decrease of E-Cadherin-1 expression 
 
Caveolin-1 (CAV1) is the main component of the caveolae membrane 
system and is known to control cell proliferation and viability by suppressing 
survivin, a member of IAP (inhibitor of apoptosis) family via a transcriptional 
mechanism involving β-catenin-Tcf/Lef-1 pathway (Torres et al. 2007). This 
protein function has been found to be involved in tumor progression and 
invasiveness (Thompson 1998; Yang et al. 1998; Ho et al. 2002) and also 
associated to multidrug resistance (Lavie, 1998). Studies have demonstrated that 
CAV1 is overexpressed in MTX-resistant colon cancer cell lines, showing a role for 
CAV1 in MTX resistance (Bender et al. 2000; Selga et al. 2008). 
 
Enolase-2 (ENO2) is glycolysis-related and is induced by hypoxia, an 
intrinsic tumorigenic property. It has been described that ENO2 plays an important 
role in tumorogenesis of colorectal cancers (Yeh et al. 2008) and it is upregulated 
in a variety of cancers (Fujiwara et al. 2002; Karnak et al. 2005; Kitakata et al. 
2007). Selga et al. (2008) showed a role for ENO2 in the MTX resistance when 
noticed an increase in sensitivity to MTX after transfected with a siENO2.  
 
Protein kinase c α (PKCα) has also been associated with multidrug 
resistance (Yu et al. 1991). The α-isoenzyme PKC phosphorylates different 
proteins promoting a wide variety of cellular responses including proliferation, 
differentiation, membrane transport, gene expression and tumor promotion 
(Martelli et al. 1999; Wang et al. 1999). Using chemical inhibitors of PKC activity, 
Noé et al. (1995) have been proposed PKC as resistance modulators in MTX 
chemotherapy. Moreover, reducing PKCα mRNA levels diminishes the MDR 
phenotype in tumor cells (Ahmad and Glazer 1993) and sensitizes cells to 
anticancer drugs, both in vitro (Wang and Liu 1998; Isonishi et al. 2000; Lahn et al. 
2004) and in vivo (Geiger et al. 1998). Selga et al. (2008) also demonstrated an 
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increase of sensitization toward MTX with a decrease in PKCα mRNA levels, 
revealing a role for PKCα in the MTX resistance. 
 
A direct interaction has been described between PKCα and CAV1 (Oka, 
Yamamoto et al. 1997). PKCα overexpression may represent an important cellular 
event in tumor progression, once in MCF-7 breast cancer cells transfected with 
PKCα, the expression of E-cadherin and β-catenin decrease, resulting in a loss of 
cell-cell adhesion and thus in a more aggressive tumor phenotype (Lahn et al. 
2004). 
 
The loss of E-cadherin is frequently associated with tumor progression 
(Behrens et al. 1989; Perl et al. 1998) and is considered a central event that 
stimulates metastasis and invasiveness of the tumors (Frixen et al. 1991; Cavallaro 
and Christofori 2004). MTX-resistant colon cancer cells showed an 
underexpression of E-cadherin (Selga et al. 2008). 
 
1.2.6.4. Overexpression of DKK1 and EEF1A1 
 
Dikkofp homolog 1 (DKK1) is a protein involved in embryonic development 
(Forget et al. 2007) and has also been described as an inhibitor of Wnt signaling 
(Rothbacher and Lemaire 2002). A role of its overexpression has been suggested in 
cancer (Monaghan et al. 1999; Gregory et al. 2003; Koch et al. 2005; Forget et al. 
2007; Voorzanger-Rousselot et al. 2007) however the precise mechanism is poorly 
understood. In MTX-resistant colon cancer cells the role of DKK1 is still unclear, 
but it seems to be related to the resistant phenotype (Selga et al. 2009). Also Katula 
et al. (2007) demonstrated that MTX inhibited DKK1 transcription, corroborating 
with the hypothesis that DKK1 overexpression could constitute a mechanism to 
overcome the MTX inhibitory effect over the transcription.   
 
Eukaryotic translation elongation factor 1A1 (EEF1A1) is an elongation 
protein factor that recruits aminoacetylated tRNAs to the A site of the ribosome 
(Thornton et al. 2003) and also its overexpression has been found in a variety of 
cancers (Alon et al. 1999; Thornton et al. 2003). It is already described that 
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EEF1A1 expression is involved in increased cell proliferation (Hassell and 
Engelhardt 1976; Grassi et al. 2007), oncogenic transformation (Tatsuka et al. 
1992), delayed senescence (Shepherd et al. 1989) and metastasis (Edmonds et al. 
1996). Furthermore, its overexpression has also been associated with MTX 
resistance (Beyer-Sehlmeyer et al. 1999) and to drug resistance toward other 
chemotherapeutic agents as well (Bertram et al. 1998; Johnsson et al. 2000), 
probably due to its inhibitory activity over apoptosis (Talapatra et al. 2002). Selga 
et al. (2009) verified that the knockdown of EEF1A1 by small interfering RNA 
(siRNA) technology in pancreatic cancer cell line sensitized the cell to MTX, 
revealing a role for EEF1A1 in MTX resistance. 
 
1.2.6.5. Increase in UGT1A family expression 
 
UDP-glucoronyltransferases are a family of enzymes involved in phase II 
metabolism, responsible for the glucoronidation of many lipophilic endogenous 
substrates such as bilirubin, estrogens, and xenobiotics. The addition of a glycosyl 
group from uridine diphosphoglucoronic acid (UDPGA) returns hydrophobic 
compounds more soluble for their elimination via bile and urine.  
Selga et al. (2009) showed that there is an overexpression in UGT1A family 
in human breast cancer cells resistant to MTX. UGT1A6, among different members 
of UGT1A family, could be the main responsible for the rise of UGT1A expression 
(Selga et al. 2009). UGT1A6 is the main UGT that mediates glucoronidation in 
human (Krishnaswamy et al. 2005). As MTX shares a phenolic structure common 
to other UGT1A substrates, UGT1A family could somehow contribute to MTX 
metabolism, thus contributing to resistance. It is also described that UGT1A 
overexpression in MTX resistant cell lines is associated with an increase in UGT1A 
transcription caused by MTX action as an inducer of increased mRNA levels and 
not due to gene amplification. This induction could occur through MTX action on 
some transcription factors involved in UGT1A induction, such as ARNT and 
AhR/ARNT (Selga et al. 2009). 
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1.2.7. Altered miRNA expression: underexpression of miR-224  
 
MicroRNAs (miRNAS) are a new class of small non-coding RNAs involved in 
RNA silencing that play a role in many biological processes (Carrington and 
Ambros 2003; Bartel 2004). They are involved in the development of many 
diseases, including cancer (Calin et al. 2002; Metzler et al. 2004; Cimmino et al. 
2005; Hayashita et al. 2005; Iorio et al. 2005; Murakami et al. 2006; Voorhoeve et 
al. 2006). Extensive studies show that miRNAs play a role in cancer pathogenesis 
and in the development of drug resistance as well (Ma et al. 2010). 
Mencia et al. (2011) showed that miR-224 is greatly underexpressed in MTX-
resistant colon cancer cells. In this work, the underexpression of miR-224 seems to 
be responsible for the increase of mRNA levels of SLC4A4, CDS2 and HSPC159 
genes in colon cancer MTX-resistant cells, thus contributing to less MTX 
cytotoxicity. This was confirmed when using Polypurine reverse-Hoogsteen 
hairpins (PPRHS) and siRNAs to knock down the miR-224 targets the cells became 
more sensitive to the MTX. SLC4A4 is a membrane transport protein responsible 
for transport of sodium and bicarbonate across the membrane in epithelial cells 
(Romero et al. 1997). As described above, alterations in membrane transport have 
shown to be a determining factor for the development of MTX resistance (Zhao and 
Goldman 2003). Differential expression of SLC4A4 can induce changes in pH 
affecting the optimal activity of RFC and therefore decreasing the amount of MTX 
inside the cell, favoring the resistance phenotype (Mencia et al. 2011). CDS2 
encodes an enzyme that is responsible for the conversion of phospatidic acid to 
CDP-diaglycerol, thus regulating the amount of phosphatidylinositol available for 
signaling (Weeks et al. 1997). Breakdown products of phosphoinositides are 
ubiquitous second messengers involved in important cellular processes such as 
cell growth and protein kinase C activity. The role of PKCα has already been 
associated with resistance to MTX (Selga et al. 2008). Its inhibition caused 
chemosensitization to MTX, thus playing an important role in MTX resistance in 
colon cancer cells (Mencia et al. 2011). HSPC159 (galectin-related protein) is part 
of the galectin family but it lacks the capacity to bind β-galactosides (Cooper and 
Barondes 1999; Cooper 2002) and its biological function still remains unknown.  
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These results demonstrate that besides all the mechanisms described before, 
the underexpression of miR-224 in its targets expression SLC4A4, CDS2 and 
HSPC159 leads to insensitivity towards MTX, favoring the resistant phenotype. 
 
2. Apoptosis in cancer and chemotherapy: p53 as an apoptotic mediator 
 
Deregulated proliferation and inhibition of apoptosis are the main 
alterations during cancer development inherent to an accumulation of oncogenic 
mutations and obviously these two altered processes represent important targets 
for therapy (Evan and Vousden 2001). Deregulation of both phenomena is a 
complex process involving numerous coupled key mechanisms of oncogenic 
proliferative signals and suppression of apoptosis. 
Originally apoptosis was described by Kerr et al. (1972) as a defined highly 
regulated form of programmed cell death characterized by progressive activation 
of specific pathways toward precise morphological and biochemical changes in the 
cell without involving an inflammatory response (Table 1).  
These morphological changes lead to the packaging of the dead cells into 
apoptotic bodies. Apoptotic bodies are subsequently recognized and swallowed by 
phagocytic cells. As a gene-directed program, apoptosis is a crucial process to 
maintain the cell´s homeostasis under physiological conditions, since it seems to be 
induced when injury exceeds the repair ability, as well as during the normal tissue 
development and like any other metabolic or developmental program, it can be 
disrupted by mutation. In fact, its deregulation is associated either as a cause or 
consequence of several pathologies ranging from neurodegenerative disorders to 
malignancy. 
Alterations in p53 pathway appear to be central in cancer development. p53 
ability to eliminate damaged cells by apoptosis is vital to regulate the cell 
proliferation in multi-cellular organisms (Huang and Strasser 2000) and can be 
activated by external or internal stimuli. Due to damaged DNA, expression of 
oncogenes, hypoxia and nucleotide depletion (Giaccia and Kastan 1998), p53 is 
activated and its transcriptional activity can induce the expression of pro-
apoptotic proteins and activate proteins involved in cell growth arrest. 
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Apoptotic cell death can occur by at least two distinct molecular signaling 
pathways based on the origin of apoptotic signal: extrinsic pathway activated by 
extracellular signals and intrinsic pathway that involves mitochondrial mediation 
and subsequent cytochrome c release, both activating the caspases, proteolytic 
enzymes responsible for dismantling the cells. 
Most of chemotherapeutic DNA-damaging agents act primarily as apoptotic-
inducers in the target cells. DNA-damaging agents apoptotic action is associated to 
activation of p53, which in turn stimulates the expression of Bcl-2 family members 
involved in the mitochondrial pathway (Fisher 1994; Kaufmann and Earnshaw 
2000). 
 
2.1. Apoptotic intrinsic pathway: cytochrome c release and MTX 
 
MTX, as DNA-damaging agent, activates the p53 pathway triggering 
apoptosis by induction of some proteins involved in the mitochondrial or intrinsic 
pathway, such as Bax and Bid. 
Currently, it is widely accepted that mitochondria play a key role in the 
regulation of apoptosis and has a main role in the apoptotic intrinsic pathway. 
Upon anticancer drugs treatment, mitochondria are induced to release cytochrome 
c. This process is dominated by the Bcl-2 protein family (Cory and Adams 2002; 
Kuwana et al. 2002). This family includes anti-apoptotic proteins, such as Bcl-XL, 
and pro-apoptotic proteins, such as Bax and Bid. The later proteins are p53 targets. 
In response to induced-stress, Bax forms a homo-oligodimer and interacts 
with of permeability transition pore (PTP) components causing the opening of 
non-specific pores in outer mitochondrial membrane (OMM) and subsequent 
cytochrome c release (Narita et al. 1998). Mitochondrial membrane 
permeabilization therefore appears to be a key initiative step in the apoptotic 
process. Once released from the mitochondria into cytosol cytochrome c interacts 
with Apaf-1 recruiting and activating pro-caspase-9, forming the apoptosome (Zou 
et al. 1999). 
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Table 1 – Cellular changes during the apoptotic process  
(Kerr et al. 1972) 
 
Activated caspase-9, in turn, cleaves and activates caspase-3 and -7 (Kim et 
al. 2005). These effector caspases are responsible for the activation of several key 
proteins leading to apoptotic characteristic biochemical and morphological 
changes (Robertson et al. 2000). 
 
3. Regulation of apoptosis by cytochrome c redox-state 
 
Cytochrome c release from the mitochondria into the cytosol is the key 
event in the apoptotic intrinsic pathway and even though it is irreversible, some 
evidences suggest that the execution phase of apoptosis is highly regulated after 
cytochrome c release (Twiddy et al. 2004; Martin et al. 2005).  
Apoptosis 
Morphological 
Asymmetric membrane without loss of integrity 
Aggregation of chromatin in the nuclear envelope 
Condensation of cytoplasm and nuclei 
Vesicle formation 
Apoptotic bodies 
Mitochondria become permeable 
Biochemical  
Active process 
Signals transduction cascades activation: activation of caspase cascade 
Non aleatory fragmentation of DNA 
Physiological 
Individual cells affected 
Induced by physiological stimuli 
Phagocytosis mostly by macrophages 
With no inflammatory response 
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Cytochrome c is a heme-protein traditionally localized in the mitochondrial 
inter-membrane and it is an essential component of the electron transport chain 
(ETC), being responsible for shuttling electrons between complexes III and IV. 
Cytochrome c exists in interconvertible reduced (heme Fe2+) or oxidized (haem 
Fe3+) forms. These two forms have different physical and biochemical properties 
(Martin et al. 2005). Reduced cytochrome c is less capable of binding to anions and 
binds less tightly to negatively charged membrane (Hancock et al. 2001) and this 
may influence the kinetics of activation of the apoptosome (Brown and Borutaite 
2008). 
Several studies where cytochrome c in its two different redox states was 
added to cell extracts demonstrated that oxidized cytochrome c induced apoptotic 
activity and reduced cytochrome c had no effect, measured by nuclear 
fragmentation or caspase-9 and -3 activities (Pan et al. 1999; Suto et al. 2005; 
Borutaite and Brown 2007).  
Borutaite and Brown (2007) demonstrated that cytochrome c when added 
to cytosolic extracts, was partially reduced and when further reduced using agents 
such as tetramethylphenylenediamine (TMPD) or ascorbate also the caspase 
activation was inhibited, whereas when cytochrome c oxidase was added to 
oxidize cytochrome c, caspase activation was enhanced.  
All these studies are in agreement with each other, showing that reduced 
cytochrome c is little or not able to induce caspase activation in cytosol, whereas 
oxidized cytochrome c induces caspase activation – Figure 3.  
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Figure 3 – Regulation of apoptosis by the redox state of cytosolic cytochrome 
c. Cytochrome c in its oxidized form (Cyt. Cox) is released, binding to Apaf-1 
forming the apoptosome which activates pro-caspase-9 leading to apoptosis. 
Cytochrome c can be reduced by several reductants, which cannot activate the 
apoptosome and therefore cannot promote apoptosis. (Adapted from 
Brown&Borutaite, 2008) 
 
Also the different redox forms of cytochrome c might have different binding 
affinities for Apaf-1 and different abilities to activate Apaf-1, after binding, whereas 
the reduced form of cytochrome c would have lower affinity to Apaf-1. Activation 
of Apaf-1 could be blocked by reduced cytochrome c when it binds to ATP needed 
for Apaf-1 activation (Chandra et al. 2006), thus the apoptosome formation, 
inhibiting apoptosis. 
However, Hampton (1998) and Kluck (1997) have demonstrated that 
cytochrome c redox state did not affect the caspase activation, thus the apoptosis 
by caspase; still they found that its activation was dependent on some structural 
features of cytochrome c.  
Furthermore, it appears that the redox state of cytochrome c may also 
regulate apoptosis upstream of caspase activation. Redox state of cytochrome c is 
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strongly regulated by the cellular redox system. In mitochondria, cytochrome c is 
in its proper location, under physiological conditions, due to an interaction with 
cardiolipin, preventing its release to the cytosol (Ott et al. 2007). Since cardiolipin 
is sensitive to lipid peroxidation, when the ROS-scavenging activity of 
mitochondrial GSH and mitochondrial glutathione peroxidase (mtGPx) is 
compromised, excessive ROS can activate the peroxidase activity of cytochrome c, 
leading to cardiolipin peroxidation (Kagan et al. 2005). Oxidized cardiolipin loses 
its affinity to cytochrome c, favoring its release from the mitochondria. This could 
be one way in which the cytochrome redox state regulates apoptosis prior 
cytochrome c release, since the reduced form of cytochrome c is unlikely to be 
capable of oxidizing cardiolipin.  
 
3.1. Cytosolic GSH and cytochrome c redox state  
 
Glutathione (L-g-glutamy-L-cysteinylglycine - GSH) is the most abundant 
intracellular tripeptide thiol and it is well established that it is one of the most 
important components in the antioxidant defense system and a major 
detoxification agent in cells via catalysis by GST and glutathione peroxidases (GPx) 
(Clark et al. 1984), maintaining the optimal redox environment for normal activity 
of the cellular proteins. Under oxidative conditions, reduced GSH is oxidized to 
glutathione disulfide (GSSG) and then reverted to GSH by glutathione reductase 
(GR) activity (Ames 1989; Ames et al. 1993). 
Beyond its antioxidant and detoxification activity, it has been also described 
the role of GSH in apoptosis in a variety of cell types (Pias et al. 2003; Okouchi et al. 
2006; Circu and Aw 2008). Apoptosis can be induced by many factors, including 
the presence of reactive oxygen species (ROS), such as hydrogen peroxide (H2O2) 
or superoxide (O2-) that can arise from a variety of cellular sources, such as 
electron leakage in mitochondria. Generally, ROS-mediated apoptosis is associated 
with a decrease in GSH levels in the cell, including mitochondrial GSH and the loss 
of intracellular redox balance. ROS production associated to the decrease of 
mitochondrial GSH levels provokes the loss of mitochondrial membrane potential 
inducing cytochrome c release. It has also been described that the intracellular GSH 
decrease may induce the cytochrome c release, through redox regulation of PTP 
Chapter I  General Introduction 
17 
 
opening and Bax translocation to mitochondria (Ghibelli et al. 1999; D'Alessio et al. 
2005). 
The released cytochrome c, is a key component for the triggering of the 
intrinsic pathway of apoptosis and, since it can exist in two redox forms, reduced 
or oxidized, it can also be influenced by the redox environment in the cytosol 
(Hancock et al. 2001). As stated before, once in the cytosol, cytochrome c needs to 
be in its oxidized state to induce apoptosis. Depletion of cytosolic GSH would 
induce the pro-apoptotic action of cytochrome c, since the cytosolic environment 
will be more oxidized and therefore the cytochrome c may be oxidized, triggering 
the apoptosis (Brown and Borutaite 2008). Under physiological conditions, the 
high GSH in cytosol will keep cytochrome c in a reduced state, whereas if the cell 
has been exposed to oxidizing conditions the cytochrome c becomes oxidized. 
Vaughn and Deshmukh (2008) have demonstrated that in healthy neurons and 
cancer cells, cytochrome c is kept in its reduced state, thus held inactive by 
increased GSH levels, generated by glucose metabolism by pentose phosphate 
pathway.  
GSH also protects proteins from irreversible oxidation by forming mixed 
disulfide linkages with cysteines in proteins. This is called s-glutathionylation and 
it is important to regulate protein function mediated by GSTs (Fratelli et al. 2002; 
Dalle-Donne et al. 2005; Shelton et al. 2005). Although there is no evidence of s- 
glutathionylation of cytochrome c in vivo, it has been demonstrated a direct 
interaction between cytochrome c and GSH in vitro (Deng 2006). 
 
4. Role of GSTs and GSH in anti-cancer drug-resistance 
 
GST family is part of cellular Phase II detoxification system composed by 
enzymes that catalyse the conjugation of GSH to a variety of endogenous and 
exogenous electrophilic compounds, protecting cellular macromolecules from their 
attack (Hayes et al. 2004).  
Human GSTs can be divided into three main super-families: cytosolic, 
mitochondrial and membrane-bound microsomal. Human cytosolic GSTs are 
extremely polymorphic and are distributed into seven classes initially based on 
Greek alphabet (newer nomenclature uses Latin script) alpha (A), Mu (M), Omega 
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(O), Pi (P), Sigma (S), Theta (T) and Zeta (Z) (Hayes and Pulford 1995; Armstrong 
1997; Hayes and McLellan 1999; Hayes, Flanagan et al. 2004). This classification is 
essentially based on > 60% share sequence identity within a class, focused on the 
more highly conserved N-terminal domains containing catalytically active tyrosine, 
cysteine or serine residues.  
 The catalytic functions of GSTs in conjugating GSH with a variety of 
electrophilic substrates is well described (Boyland and Chasseaud 1969). Apart 
from its functions in detoxification, GSTs also play a role in death signaling 
regulation via mitogen-activated protein kinase (MAPK) pathway, inducing either 
extrinsic or intrinsic apoptotic pathway when the cell is under oxidative stress 
(Adler et al. 1999). The GSTs regulation lies in the interaction between c-Jun N-
terminal kinases (JNK) and apoptosis signal-regulating kinase (ASK). This 
interaction is activated by GST-mediated negative regulation in response to 
cellular stress. ASK1 is a mitogen-activated protein kinase kinase kinase 
responsible for activation of JNK and p38 pathways leading to stress-induced 
apoptosis. Both JNK and ASK1 are maintained in a low level in non-stressed cells 
due to the interaction with GST. GST overexpression blocked ASK1 
oligomerization, repressing ASK1-dependent apoptotic cell death via JNK-pathway, 
since JNK is responsible for phosphorylation of transcription factors involved in 
apoptosis (Cho et al. 2001). This can possibly explain the resistant phenotype 
toward chemotherapy agents in some drug resistant cells, even when the drug is 
not a substrate for GST-mediated conjugation to GSH.  A variety of anticancer 
agents induce apoptosis via JNK and p38 pathways. 
 Therefore, GSTs can have two different roles in the development of drug 
resistance: via direct detoxification as well as inhibiting MAPK-induced apoptosis, 
thus a large number of tumor types exhibit high levels of GSTs and GSH as well.  
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Objectives 
 
 
The main objective of the present work is to assess the potential 
involvement of the apoptotic regulation by cytochrome c redox state in the 
development of the resistance to MTX in human breast cancer cells.  As described 
above, drug resistance is a complex process in which several pathways can be 
involved. In this study we propose a new model involving the cytochrome c redox 
state in regulation of MTX-dependent apoptosis. To achieve that, we firstly 
evaluate the effect of cytochrome c redox-state in sensitivity to MTX and in MTX-
dependent apoptotic effect using cytochrome c- reducer agents such as TMPD, 
ascorbate or reduced GSH.  
GSTs and GSH have been associated to drug-resistance mechanisms. The 
overexpression of some cytosolic GSTs isoforms in MCF-7 breast cancer cells can 
be the link between the role of the cytochrome c redox-state in apoptotic 
regulation and MTX-resistance. We aim to find out their roles in redox-state of 
cytochrome c and its contribution to MTX resistance in human cancer cells. 
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1. Abstract 
 
1.1. Background  
 
Methotrexate is a chemotherapeutic agent used to treat a variety of cancers. 
However, the occurrence of resistance limits its effectiveness. Cytochrome c in its 
reduced state is less capable of triggering the apoptotic cascade. Thus, we set up to 
study the relationship among redox state of cytochrome c, apoptosis and the 
development of resistance to methotrexate in human breast cancer cells. 
 
1.2. Results 
 
Cell incubation with cytochrome c-reducing agents, such as 
tetramethylphenylenediamine, ascorbate or reduced glutathione, decreased the 
mortality and apoptosis triggered by methotrexate. Conversely, depletion of 
glutathione increased the apoptotic action of methotrexate, showing an 
involvement of cytochrome c redox state in methotrexate-induced apoptosis. 
Methotrexate-resistant cells showed increased levels of endogenous reduced 
glutathione and a higher capability to reduce exogenous cytochrome c. Using 
functional genomics we detected the overexpression of GSTM1 and GSTM4 in 
methotrexate-resistant MCF7 breast cancer cells.The inhibition of these isoforms 
of GSTM caused an increase in methotrexate cytotoxicity in sensitive cells.  
 
1.3. Conclusions 
 
We conclude that overexpression of specific GSTMs, GSTM1 and GSTM4, 
together with increased endogenous reduced glutathione levels help to maintain a 
more reduced state of cytochrome c which, in turn, would decrease apoptosis, thus 
contributing to methotrexate resistance in human cancer cells. 
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2. Introduction 
 
Methotrexate (MTX) is a chemotherapeutic agent widely used, alone or in 
combination with other chemotherapeutic agents, for the treatment of a range of 
cancers, such as breast cancer, osteosarcoma, head and neck cancer, lymphoma 
and acute lymphoblastic leukemia (Jolivet et al. 1983). As a structural analogue of 
folic acid, MTX is a high affinity inhibitor of dihydrofolate reductase (DHFR) by 
competing with dihydrofolate for the active site. DHFR catalyzes the NADPH-
dependent reduction of dihydrofolate to tetrahydrofolate involved in the 
biosynthesis of thymidylate, hypoxantine and glycine, needed for DNA synthesis 
(Blakley and Cocco 1984; Noe et al. 1995; Chu et al. 1996). Once DHFR is inhibited 
by MTX, there is suppression of DNA synthesis and cell proliferation is affected. 
However, the main drawback of using MTX in cancer therapy is the occurrence of 
resistance upon treatment, thus compromising its effectiveness. Several MTX 
resistance mechanisms have been described such as gene amplification of the 
DHFR locus (Alt et al. 1978; Sirotnak et al. 1981), deficiency in MTX transport 
(Gorlick, Goker et al. 1997; Liani et al. 2003) or MTX polyglutamation (Haber et al. 
1981), expression of the MDR phenotype and mutations of the target (DHFR 
protein) (Selga et al. 2008). Altered gene or miRNA expression also contribute to 
MTX resistance such as increases in AKR1C1 (Mencia et al. 2010), S100A4 (Selga et 
al. 2008), caveolin-1, enolase-2, PRKCA (Selga et al. 2009), DKK1, EEF1A1, and 
UGT1A family (de Almagro et al. 2011; Mencia et al. 2011), and the decrease of E-
Cadherin-1 (Selga et al. 2009) or miR-224 (Mencia et al. 2011).  
Reduced glutathione (GSH) and Glutathione S-transferases (GSTs) have 
been implicated in the development of drug resistance in cancer chemotherapy 
(Tew 1994; McLellan and Wolf 1999). The GSTs enzymatic family belongs to a 
Phase II detoxification program functioning as a cellular protection from attack by 
reactive electrophiles associated to environmental stresses and drugs (Townsend 
and Tew 2003). This family is mainly responsible for the conjugation of GSH to 
electrophilic compounds and includes three main types, cytosolic, mitochondrial 
and membrane-bound microsomal. Cytosolic GSTs are divided into seven classes: 
alpha (A), Mu (M), Omega (O), Pi (P), Sigma (S), Theta (T) and Zeta (Z) [20-23]. 
GSTs are thought to be involved in the development of drug resistance via direct 
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detoxification or by regulation of the MAP kinase pathway, specifically JNK-
pathway as reviewed in (Townsend and Tew 2003).  
Cytochrome c is a heme-protein bound to the mitochondrial inner 
membrane by an interaction with the anionic phospholipid cardiolipin, which 
keeps cytochrome c in its proper location and prevents its release to the cytosol 
(Ott et al. 2007). Under physiological conditions, cytochrome c is responsible for 
the electron transfer between complexes III and IV of the mitochondrial electron 
transport chain whereas under oxidative stress, the peroxidase activity of 
cytochrome c is activated, cardiolipin becomes peroxidized, and loses its affinity 
for cytochrome c allowing its release to the cytosol (Kagan et al. 2005; Belikova et 
al. 2006). Once in the cytosol, cytochrome c can induce apoptosis only in its 
oxidized form (Hancock et al. 2001; Suto et al. 2005; Borutaite and Brown 2007; 
Brown and Borutaite 2008; Li et al. 2008). The presence of high levels of cytosolic 
GSH holds the released cytochrome c inactive in a reduced state, thus preventing 
the progression of the apoptotic cascade (Hancock et al. 2003; Vaughn and 
Deshmukh 2008).  
In this study, we investigated the effect of the reduction state of cytochrome 
c on MTX sensitivity and apoptosis and its relationship with the different GSTs 
overexpressed in breast cancer cells resistant to MTX, to evaluate a possible 
connection between GSTs and GSH in the reduction state of cytochrome c and the 
development of MTX resistance. 
 
3. Materials and Methods 
 
3.1. Cell lines and cell culture 
 
Human breast cancer MCF7 and 10-6M MTX-resistant MCF7 (MCF7-R) cell 
lines were used. Resistant cells were obtained previously in the laboratory upon 
incubation with stepwise concentrations of MTX (Almirall, Barcelona, Spain) as 
described in (Selga et al. 2008). In all experimental procedures, cells were grown 
in Ham’s F12 medium lacking the final products of DHFR activity, glycine, 
hypoxanthine and thymidine (-GHT), supplemented with 7% v/v dialyzed fetal 
bovine serum (GIBCO, Life Technologies, Madrid, Spain), 14mM sodium 
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bicarbonate (1.176g/l), penicillin G (100U/ml) and streptomycin (100mg/l). Cells 
were maintained at 37ºC in a humidified atmosphere of 5% CO2 in air. Before 
reaching 70% confluence, cells were sub-cultured by treatment with 0.05% trypsin 
in PBS 1X. All these components were purchased from Sigma-Aldrich (Madrid, 
Spain). 
3.2. Cell viability assay 
 
Cell viability was assessed by the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay (Mosmann 1983) in 6-well dishes. Cells were 
incubated with 0.25% MTT and 270µM of sodium succinate (Sigma-Aldrich, 
Madrid, Spain) and allowed to react for 2h at 37ºC. The medium was removed and 
1ml of the solubilization reagent (0.57% acetic acid and 10% SDS (Sodium Dodecyl 
Sulfate) in DMSO (dimethyl sulfoxide) was added (Applichem, Ecogen, Barcelona, 
Spain). Cell viability was measured at 570nm in a WPA S2100 Diode Array 
Spectrophotometer. The results were expressed as percentage of cell survival 
relative to the control (untreated cells).  
 
3.3. Microarrays 
 
Gene expression was analyzed by hybridization to GeneChip® Human 
Genome U133 PLUS 2.0 microarrays from Affymetrix, containing 54,675 
transcripts and variants. Total RNA for cDNA arrays was prepared from triplicate 
samples from both control and resistant cells using the RNAeasy Mini kit (Qiagen, 
Madrid, Spain) following the recommendations of the manufacturer. The integrity 
of the RNA species was checked using the Bioanalyzer 2100 system (Agilent, 
Madrid, Spain). Labeling, hybridization and detection were carried out following 
the manufacturer’s specifications.  
 
3.4. Microarrays data analysis 
 
Quantification was carried out with GeneSpring GX 12.0 software (Agilent, 
Madrid, Spain), which allows multi-filter comparisons using data from different 
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experiments to perform the normalization, generation of lists and the functional 
classification of the differentially expressed genes. The input data was subjected to 
preprocess baseline transformation using the RMA summarization algorithm using 
the median of control samples. After grouping the triplicates of each experimental 
condition, lists of differentially expressed genes could be generated by using 
volcano plot analysis. T-test unpaired was applied using asymptotic p-value 
computation and multiple testing correction of Benjamini-Hochberg false 
discovery rate, FDR. The expression of each gene was reported as the ratio of the 
value obtained for the resistant condition relative to the control condition after 
normalization and statistical analysis of the data. The corrected p-value cut-off 
applied was of <0.05; then the output of this statistical analysis was filtered by fold 
expression, selecting specifically those genes that had a differential expression of 
at least 2-fold. 
 
3.5. RT-Real-Time PCR 
 
Total RNA was extracted using the UltraspecTM RNA reagent (Biotecx, 
Ecogen, Barcelona, Spain) following the manufacturer’s instructions. 
Complementary DNA (cDNA) was synthetized in a total volume of 20µl by mixing 
1µg of total RNA, 125ng of random hexamers (Roche, Mannheim, Germany), in the 
presence of 75mM KCl, 3mM MgCl2 , 50mM Tris-HCl buffer, pH 8.3, 10mM 
dithiothreitol (Invitrogen, Life Technologies, Madrid, Spain), 20 units of RNAsin 
(Promega, Madrid, Spain), 0.5mM dNTPs (Applichem, Ecogen, Barcelona, Spain) 
and 200 units of MLV-reverse transcriptase (Invitrogen, Life Technologies, Madrid, 
Spain). The reaction mix was incubated at 37ºC for 1h and the cDNA product was 
used for subsequent amplification. 
Gene expression levels were quantified by SYBR Green RT-Real Time PCR 
reaction in a final volume of 20µl with specific forward and reverse primers, using 
the StepOnePlusTM detection system (Applied Biosystems, Life Technologies, 
Madrid, Spain). The sequences of the forward and reverse primers (Sigma-Aldrich, 
Madrid, Spain) are given in Table 2.  
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Changes in gene expression were calculated using the quantitative ΔΔCt 
method and normalized against Hypoxanthine-phosphoribosyl transferase (HPRT) 
in each sample. 
 
Table 2 – Primer sequences. The sequences for the forward and reverse primer for detection of 
GSTM1, GSTM4 and HPRT mRNA levels used for RT-Real Time PCR are given. 
 
3.6. Inhibition of GSTM1 and GSTM4 expression levels 
 
GSTM1 and GSTM4 expression was inhibited by specific PPRH-hairpins (hp), 
hpGSTM1 and hpGSTM4, respectively (de Almagro et al. 2009; de Almagro et al. 
2011). The Triplex-Forming Oligonucleotide Target Sequence Search software 
(M.D. Anderson Cancer Center, Houston, TX) (spi.mdanderson.org/tfo/) was used 
to design the hairpins. BLAST analyses were performed to check for the specificity 
of each sequence. Cells were plated in 6-well dishes in 1 ml of medium the night 
before transfection and each hairpin was mixed with N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP) (Roche, 
Mannheim, Germany) at the appropriate oligonucleotide–DOTAP molar ratio 
(1:100) for 15 min at RT before lipofecting the cells. The sequences of the hairpins 
(Sigma-Aldrich, Madrid, Spain) are listed in Table 3. 
For RNA determination, cells were transfected and total RNA was extracted 
30h later. Gene expression was quantified as described above.   
For viability assays, cells were incubated with each hairpin for 24h before MTX 
treatment. Survival was determined after 3 days  
 
 
 
 
Gene Forward (5’-3’) Reverse (5’-3’) 
GSTM1 TGAAGCCTCAGCTACCCACT AACCAGTCAATGCTGCTCCT 
GSTM4 TTTCCTCGCCTATGATGTCC GCTGAGTATGGGCTCCTCAC 
HPRT TGCTCGAGATGTGATGAAGG TCCCCTGTTGACTGGTCATT 
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Table 3 – Hairpin sequences. The sequences for the polypurine reverse Hoogsteen hairpins used 
for specific inhibition of GSTM1, GSTM4, as well as the scrambled negative control are given. 
 
3.7. Apoptosis 
 
Apoptosis was determined by the Rhodamine 123/Propidium Iodide assay. 
Cells (6x104) were plated in 6-well dishes, and treated with the different agents 
(TMPD, ascorbate, veratridine) alone or in combination with MTX for the indicated 
times and concentrations. Then cells were incubated for 30min with 5µl of 
Rhodamine 123 (1µg/µl). All the cells in each well were harvested and centrifuged 
at 800 x g for 5min. The cell pellet was washed twice with 1ml of PBS 1X + 1%BSA 
solution and resuspended in 500µl of PBS 1X + BSA 1% solution containing 0.5µl PI 
(5µg/µl). The entire procedure was performed at 4ºC. All these reagents were 
purchased from Sigma-Aldrich (Madrid, Spain). Samples were analyzed by flow 
cytometry in the Coulter Epics XL™ cytometer (Beckman, Barcelona, Spain) at an 
excitation wavelength of 488 nm by reading the fluorescence of rhodamine123 at 
525 nm. Cells that were negative for both rhodamine123 and PI were counted as 
the apoptotic population. Summit v4.3 software was used to analyze the data. 
 
3.8. Oxygen consumption assay 
 
Cellular oxygen consumption was monitored polarographically with a 
Clark-type oxygen electrode using Hansatech Oxygraph Measurement System 
(Hansatech, Norfolk, UK). The assay was performed using 6x104cells/ml in the 
presence or in the absence of 5µM TMPD in 1ml of PBS (pH 7.4) as experimental 
medium at 37ºC. Oxygen consumption was measured either in the absence or the 
presence of TMPD during 5 min for each condition and determined by the slope 
calculated directly by the OxygraphPlus Software. 
Hairpin Sequence (5’-3’) 
hpGSTM1 GAAGGGGAGGGAAGAGAGAAGTTTTTGAAGAGAGAAGGGAGGGGAAG 
hpGSTM4 GGAGAAGAAGAAAAGGGGGAAGTTTTTGAAGGGGGAAAAGAAGAAGAGG 
hpSC AAGAGAAAAAGAGAAAGAAGAGAGGGTTTTTGGGAGAGAAGAAAGAGAAAAAGAGAA 
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3.9. GSH endogenous levels 
 
Endogenous GSH levels were determined using the Glutathione Assay Kit, 
Fluorimetric (Sigma-Aldrich®) based on a fluorimetric reaction catalyzed by GSTs 
between monochlorobimane, a thiol probe, and GSH. Briefly, the assay was 
performed with 6x104 sensitive and resistant MCF7 cells and the formation of the 
fluorescent adduct GSH-monochlorobimane was monitored at 390nm for 
excitation and 478nm for emission during 1h. 
3.10. Exogenous cytochrome c reduction by cytosolic extracts 
 
Cytosolic extracts were obtained from MCF7 cells. Cells were collected in 
ice-cold PBS by scraping and centrifuged at 1500 x g for 10 min. The cell pellet was 
resuspended in 3ml of lysing buffer prepared according to Borutaite and Brown 
(2007) and homogenized in Glass/Teflon Potter Elvehjem homogenizer (20 
strokes). The homogenate was further centrifuged in the same conditions as above 
and the supernatant was further centrifuged at 22,000 x g for 30 min and the 
resulting supernatant corresponds to the cytosolic extract. The entire procedure 
was performed at 4ºC. The reduction of exogenous cytochrome c by cytosolic 
extracts (100µg/ml of total protein) was followed spectrophotometrically. The 
analysis measured the absorbance spectra between 500 and 600nm wavelengths 
after incubation for 15min at 37ºC of exogenous cytochrome c (10µM) with 
cytosolic extracts from sensitive or resistant MCF7 cells. Reduction level of 
cytochrome c was expressed as absorbance at 550 nm minus absorbance at 535 
nm and was normalized to the total protein concentration of cytosolic extract used. 
 
3.11. Statistical analysis 
 
Data are presented as the mean ± SE for at least three different experiments. 
Analyses were performed using SPSS v.18.3 software. Differences with p-value 
<0.05 were considered significant. 
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4. Results and Discussion 
 
4.1. Effect of TMPD and ascorbate on the cytotoxicity produced by 
methotrexate tetramethylphenylenediamine (TMPD) and 
ascorbate 
 
TMPD and ascorbate have been described as external reductants of 
cytochrome c both in cytosol and mitochondria (Sarti et al. 1992; Nishimura et al. 
2001; Borutaite and Brown 2007). In this direction, we used both agents to study 
the role of the reduced state of cytochrome c in the sensitivity to methotrexate. 
First, the reduction of cytochrome c by TMPD treatment in MCF7 cells was 
confirmed by determining the changes in O2 consumption using an oxygraph upon 
treatment with this chemical reagent. One of the classic end-points to analyze 
mitochondrial function is to assess the changes in oxygen consumption since O2 is 
the ultimate electron acceptor (Pan et al. 1999). This method is commonly used 
(Clarke et al. 1984; Sarti et al. 1992; Nishimura et al. 2001; Howarth et al. 2006; 
Ripple et al. 2010), it calculates the variation of O2 concentration over time and 
offers the unique advantage of being able to add other components during the 
experiment. The slope of the graph represents the O2 consumption rate. As shown 
in figure 4, TMPD addition increased O2 consumption as represented by a steeper 
slope 0.5865 nmol O2/ml/min compared to basal consumption rate 0.0335 nmol 
O2/ml/min. 
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Figure 4 – O2 consumption analysis upon treatment with TMPD. 
Representative image of oxygen concentration determination over time in cell 
extracts under basal conditions and after treatment with 5µM TMPD (a). The 
results are expressed as the O2 consumption rate in each condition and represent 
mean value ± SE of three independent experiments (b). * p<0.05. 
 
MCF7 cells were incubated with 5µM TMPD or 300µM ascorbate, either 
alone or in combination with 30nM MTX and cell viability was determined after 3 
or 6 days, respectively. The incubation with TMPD and ascorbate started 6h before 
the addition of MTX. The presence of TMPD or ascorbate, which alone did not 
cause significant cell death, decreased the cytotoxic effect of MTX (Figure 5a, b). 
The reduction in cytotoxicity was more evident in the presence of TMPD with a 
recover in cell survival of 26%. The combination of MTX with ascorbate was less 
effective as the presence of ascorbate only counteracted the action of MTX by 14%. 
Since the cytotoxic effect of MTX decreased in the presence of these two reducing 
agents we could hypothesize that the redox state of cytochrome c might be 
involved in the sensitization of cells to MTX-induced apoptosis.  
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Figure 5 – Effect of TMPD or ascorbate (ASC) in combination with MTX on cell 
viability. Cells (6x104) were incubated in 1 ml of medium with TMPD (a) or ASC 
(b) either alone or in combination with MTX, at the indicated concentrations, for 3 
or 6 days, respectively, and cell viability was determined using the MTT assay. Pre-
treatment with TMPD or ASC was performed 6h before MTX incubation. Results 
are expressed as % of surviving cells compared to the control (untreated cells) and 
represent the mean ± SE of 3 experiments. * p<0.05. 
 
4.2. TMPD and ascorbate decrease the apoptotic effect of MTX 
 
It has been demonstrated that MTX can induce apoptosis mediated by 
cytochrome c release (Pidgeon et al. 2003; Huang et al. 2005). For this reason, we 
wanted to get further insight into the role of cytochrome c redox state in MTX-
induced apoptosis. Levels of apoptosis were determined by the loss of 
mitochondrial membrane potential (MMP) using the Rhodamine 123/Propidium 
Iodide assay. Incubation with 50nM or 100nM MTX revealed an increase in 
apoptosis of 1.65-fold and 1.9-fold, respectively, referred to untreated cells. 
Treatment with TMPD (Figure 6a) or ascorbate (Figure 6b) before MTX prevented 
this apoptotic effect by 37% and 20%, respectively. Thus, by reducing cytochrome 
c with either TMPD or ascorbate, we were able to decrease MTX-induced 
apoptosis. 
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Since TMPD was shown to be freely permeable across cytoplasmic and 
mitochondrial membranes (Sarti et al. 1992) the reduction of cytochrome c could 
take place in the mitochondria or after its release, as shown by Boturaite and 
Brown (2007). Regardless the exact mechanism, it is clear from our results that the 
reduced state of cytochrome c correlates with a lower proapoptotic effect of MTX. 
 
Figure 6 – Effect of TMPD and ascorbate (ASC) on apoptosis induced by MTX. 
Cells were incubated with TMPD (a) or ASC (b) either alone or in combination with 
MTX, at the indicated concentrations for 18h. Pre-treatment with TMPD or 
ascorbate was performed 12h before MTX incubation. Apoptosis was assessed by 
changes in mitochondrial membrane potential determined using the Rhodamine 
123/Propidium Iodide assay and it is expressed as fold change compared to the 
control and represent the mean ± SE of 3 experiments. *p>0.05, **p>0.01, 
***p>0.001. 
 
4.3. Effect of addition or depletion of GSH on MTX action 
 
The redox state of cytochrome c is partially responsible for its apoptotic 
activity. Our results showed that exogenous reducing agents of cytochrome c were 
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able to modulate the response towards MTX (figures 5 and 6). It has been 
described that GSH can reduce cytochrome c (Hancock et al. 2001; Piasentier et al. 
2003; Suto et al. 2005; Abdellatif et al. 2007), and therefore we wanted to study 
whether GSH could exert a role in MTX resistance in MCF7 cells. 
 
GSH is one of the most important regulators of intracellular redox balance, 
performing an antioxidant cell protective action, cycling between its reduced 
(GSH) and oxidized forms (GSSG) (Ghibelli et al. 1999). Reactive oxygen species 
(ROS) mediated apoptotic signaling is associated with a decrease of cellular GSH 
levels and loss of cellular redox balance (Circu and Aw 2008) and high levels of 
GSH have been associated to drug resistance (Estrela et al. 2006).  
As shown in Figure 7, incubation with exogenous GSH decreased the 
cytotoxicity induced by MTX. These results suggest that a more reduced state of 
cytochrome c correlates with less MTX cytotoxicity, as previously observed with 
TMPD or ASC. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Effect of GSH treatment on the cytotoxicity caused by MTX. MCF7 
parental cells (6x104) were plated in 1ml medium and treated with 1μM GSH (light 
grey bars) for 2h before incubation with MTX. Survival was assessed by the MTT 
assay 4 days later. Results are expressed as % of survival compared to non treated 
cells and represent the mean ± SEM of at least 3 experiments. **p<0.01, 
***p<0.001. 
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To explore the role of GSH on MTX-dependent apoptosis we used 
veratridine to decrease GSH levels (Jordan et al. 2002). As shown in Figure 8, the 
apoptotic effect provoked by the combination of veratridine plus MTX was higher 
than the sumatory of both agents by themselves. Interestingly, the addition of 1µM 
GSH decreased MTX-induced apoptosis and counteracted the increase in apoptosis 
caused by veratridine. 
 
 
Figure 8 - Effect of veratridine (VERA) and GSH on MTX induced apoptosis. 
Cells were incubated with veratridine alone or in combination either with MTX or 
MTX plus GSH, at the indicated concentrations. Pre-treatment with veratridine was 
performed 6h before MTX incubation. Incubation with exogenous GSH started 8h 
before the addition of MTX. In the triple combination, cells were incubated 2h with 
GSH, then veratridine was added and 6h later treatment with MTX was performed. 
Apoptosis was assessed 18h after MTX addition by changes in mitochondrial 
membrane potential determined using the Rhodamine 123/Propidium Iodide 
assay and is expressed as fold change compared to untreated cells. Results 
represent the mean ± SE of 3 different experiments. Staurosporine (STP) was used 
as a positive control. * p<0.05. 
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These results indicate a possible role of GSH in MTX-induced apoptosis. It 
has been suggested that endogenous GSH contributes to maintain cytochrome c in 
its reduced state under physiological conditions and prevents its apoptotic effect 
(Hancock et al. 2001; Hancock et al. 2003; Vaughn and Deshmukh 2008; Ripple et 
al. 2010). A lower reduced environment caused by GSH depletion would favor 
cytochrome c induced apoptosis upon MTX incubation.  
GSH endogenous levels were determined in situ in sensitive and resistant 
cells. As shown in figure 9a, GSH content was 6.2 times higher in resistant cells, 
indicating that the detoxifying capacity of the cytoplasm in resistant cells was 
higher than in sensitive cells. To analyze this, exogenous cytochrome c was 
incubated with either sensitive or resistant cytosolic extracts. Changes in 
cytochrome c redox state were measured spectrophotometrically as described. 
The results in Figure 9b confirmed that resistant cells had a higher capacity to 
reduce the exogenous cytochrome c (60%). These results support the idea that the 
higher reduced environment present in MTX-resistant cells would contribute to 
overcome the apoptotic stimuli, in this case produced by MTX, and favor the 
resistant phenotype. 
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Figure 9 - Endogenous GSH levels and cytochrome c redox capacity in 
cytosolic extracts. (a) GSH endogenous levels were determined as described in 
Methods in sensitive and MTX-resistant MCF7 cells (6x104). GSH content was 
calculated as nmols of GSH/mg of total protein (mean ± SEM). The results are 
expressed as the ratio between resistant and sensitive cells. (b). Cytosolic extracts 
from sensitive and resistant cells were obtained and incubated for 15min with 
10μM of exogenous cytochrome c. A sample with DTT and no cell extract was 
considered as the maximum cytochrome c reduction value. Reduction level of 
cytochrome c was calculated as absorbance at 550 nm minus absorbance at 535 
nm. The results are expressed as the percentage of reduction observed in the 
resistant compared to the sensitive cell extracts and represent the mean± SEM of 
at least three experiments. * p<0.05. 
 
4.4. Endogenous levels of GST in sensitive and MTX resistant MCF7 cells 
 
The treatment with exogenous GSH prior to MTX had the same effect on cell 
viability as preincubation with TMPD or ascorbate, both known cytochrome c 
reducing agents. Therefore, an increase in GSH would keep cytochrome c reduced 
and could help the cells to reduce the apoptotic effect induced by MTX. To explore 
more in detail this possibility and its mechanism in our model of MTX resistance 
we searched for genes related with GSH and the balancing redox environment of 
the cell. 
Whole genome expression microarrays of sensitive and MTX-resistant 
MCF7 cells had been previously performed in the laboratory (Selga et al. 2009) and 
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deposited in the GEO database with series accession number GSE16648. 
Interestingly, analyses of the data demonstrated that different isoforms of the GST 
family, namely GSTM1, GSTM2 and GSTM4, were overexpressed in MCF7 resistant 
cells compared to their sensitive counterparts (Table 4). 
 
Table 4 - Differentially expressed GSTs in MCF7 MTX-resistant cells. Microarray data analysis 
was performed with GeneSpring GX 12.0 software as described. For each GSTM isoform, it is 
expressed the mean of the raw value in sensitive and resistant cells, the fold change in expression 
after normalization of the data, as well as, the corrected p-value after Benjamini-Hochberg FDR 
filtering 
 
Several examples in the literature have established a link between GSTM1 
and GSTM4 overexpression with drug resistance (Luo et al. 2009; Hosono et al. 
2010; Moyer et al. 2010; Pasello et al. 2011; Wang et al. 2011), for this reason 
GSTM1 and GSTM4 were selected for further study. On the other hand, GSTM2 is a 
muscle-specific human GSTmu isoform specially enriched in in the cytoplasm of 
skeletal and cardiac muscle (Abdellatif et al. 2007). Although both increased or 
decreased expression of GSTM2 have been related to cancer predisposition or 
promotion, such as lung cancer (Tang et al. 2011) or ovarian teratoma (Han et al. 
2011), no clear evidence between GSTM2 increased levels and drug resistance has 
been reported, and therefore this isoform was not further studied.  
GSTM1 and GSTM4 mRNA levels were validated by RT-Real Time PCR in 
sensitive and MTX-resistant cells. As it can be observed in Figure 10 both GSTM1 
(a) and GSTM4 (b), were overexpressed 2.2 and 2.77-fold, respectively, in MCF7 
resistant cells, confirming GSTs overexpression detected in the microarray 
experiments. 
 
 
Gene Symbol Raw resistant Raw sensitive Fold Change Corrected   p-value 
GSTM1 129 58 2.2 0.01288 
GSTM2 182 76 2.4 0.02732 
GSTM4 151 67 4.8 0.02732 
Chapter II 
The redox state of cytochrome c modulates resistance to methotrexate in human breast cancer 
48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – Validation of GSTM1 and GSTM4 overexpression in MCF7 
MTXresistant cells. GSTM1 (a) and GSTM4 (b) mRNA expression levels were 
determined by RT-Real Time PCR in sensitive and 10-6M MTX-resistant MCF7 cells. 
Results are expressed as fold change in expression compared to sensitive cells and 
are the mean ± SE of at least 3 different experiments. **p <0.01, ***p <0.001. 
bsorbance at 535 nm. The results are expressed as the percentage of reduction 
observed in the resistant compared to the sensitive cell extracts and represent the 
mean± SEM of at least three experiments. * p<0.05. 
 
4.5. Inhibition of GSTM1 and GSTM4 increases the cytotoxicity produced 
by MTX 
 
To establish a role of GSTs in the sensitivity to MTX, we silenced GSTM1 and 
GSTM4 using specific template polypurine hairpins, a new class of molecules for 
specific and effective gene silencing developed in the laboratory (de Almagro et al. 
2009; de Almagro et al. 2011).  
As it can be observed in Figure 11c & d, MTX cytotoxicity increased when 
either GSTM1 or GSTM4 were inhibited by specific PPRH-hairpins (Figure 11a & 
b), demonstrating the role of these specific GSTs in diminishing the cytotoxicity 
produced by MTX. 
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Figure 11 - Effect of GSTM1 and GSTM4 inhibition on GSTM1 and GSTM4 
mRNA levels, and on sensitivity towards MTX. MCF7 cells (6x104) were plated 
in 1ml of medium and transfected 18h later with specific hairpins against GSTM1 
(hpGSTM1) (a) and GSTM4 (hpGSTM4) (b). mRNA levels were determined 30h 
after transfection. Results are expressed as changes in expression compared to the 
control non-transfected cells and are the mean ± SE of at least 3 different 
experiments. A scrambled hairpin was used as a negative control (hpSC). 
Cytotoxicity upon transfection with hpGSTM1 (c) or hpGSTM4 (d) alone or in 
combination with MTX. MCF7 cells (6x104) were plated in 1ml of medium and 
transfected 18h later with either hpGSTM1 or hpGSTM4. MTX was added 24h after 
transfection and viability assayed by MTT 3 days later. Results are expressed as % 
of survival compared to the control non-transfected cells and are the mean ± SE of 
at least 3 different experiments. *p <0.05, **p <0.01. 
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GSTs, in addition to their classic catalytic functions in detoxification of 
electrophilic compounds, are also involved in the regulation of other mechanisms 
that impact cell survival pathways, such as the JNK-pathway (Townsend and Tew 
2003; Tew and Townsend 2012). Interestingly, overexpression of GSTM1 (Cho et 
al. 2001) and GSTP (Adler et al. 1999) has been described to prevent the activation 
of MAPK pathway, thus avoiding the apoptosis cascade. This link with MAPK-
mediated signaling could provide a possible mechanism of action of GST in drug-
resistant cells. In addition, overexpression of GSTs has been associated with 
resistance to many therapeutic drugs (Townsend and Tew 2003), even if they are 
not GSTs substrates (Tew 1994; Fan and Chambers 2001). Another observation 
that argues in favor of GSTs playing a role in the modulation of apoptosis is the 
finding that Bee Venom, an inducing-apoptosis agent, increases the expression of 
apoptotic proteins, e.g. Bax, Bid, p53, p27, cytochrome c but decreases the 
expression of anti-apoptotic proteins like Bcl-2, Bcl-xL, and also GSTs (IP et al. 
2008). Although there is no evidence of s-glutathionylation of cytochrome c in vivo, 
direct interaction between GSH and cytochrome c has been described in vitro 
(Deng 2006). Therefore, GST might help to maintain, directly or indirectly, 
cytochrome c in a reduced state. 
According to our results, inhibition of GSTM1 and GSTM4 increases the 
sensitivity to MTX in sensitive cells, which is in keeping with the overexpression of 
these particular isoforms in breast cancer cells resistant to MTX. These 
observations suggest a role of GSTs in MTX drug resistance. 
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5. Conclusions 
 
There is a relationship between cytochrome c redox state, apoptosis and 
development of MTX-resistance. In the presence of exogenous reducing agents of 
cytochrome c such as TMPD, ascorbate or GSH, cells were less prone to apoptosis, 
which led to a lower MTX cytotoxicity. On the other hand, depletion of endogenous 
GSH using veratridine caused an increase in the apoptotic action of MTX, which 
was reverted by the addition of exogenous GSH. Furthermore, endogenous levels of 
GSH were higher in MTX-resistant cells. These observations suggest that 
cytochrome c redox state modulates MTX sensitivity. Inhibition of GSTM1 and  
GSTM4, which are overexpressed in MTX-resistant cells, caused an increase 
in MTX cytotoxicity. In summary, we conclude that in MCF7 breast cancer cells the 
overexpression of specific GSTs and increased GSH levels contribute to a more 
reduced environment. Thus, the presence of a more reduced cytochrome c would 
help the cells to avoid apoptosis and contribute to the resistant phenotype. 
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Methotrexate is a DNA-damaging agent widely used in chemotherapy to 
treat a variety of cancers, triggering p53-dependent apoptotic intrinsic pathway. 
However, the occurrence of resistance limits its effectiveness.  
Cytochrome c, as a key component of apoptotic intrinsic pathway, is less 
capable of inducing apoptotic cascade when is in its reduced state. Thus, in the 
present work MCF7 breast cancer cells were used as a model to set up a study of 
the relationship among redox state of cytochrome c, apoptosis and the 
development of resistance to methotrexate.  
The redox state of cytochrome c is mainly regulated by the intracellular 
redox environment in which GSH and GST have an important role. In the presence 
of exogenous reducers of cytochrome c (TMPD, ascorbate, GSH), methotrexate-
treated cells showed less mortality and apoptosis. On the other hand, depletion of 
endogenous GSH increased the apoptotic action of methotrexate, which was 
reverted by the addition of exogenous GSH. Furthermore, resistant cells to 
methotrexate showed higher endogenous levels of GSH. MTX-resistant cells 
displayed an overexpression of specific GSTMs, GSTM1 and GSTM4, and when 
inhibited an increase in methotrexate cytotoxicity in sensitive cells arose.  
According to the results, overexpression of specific GSTs and increased 
endogenous GSH levels appear to help to keep the cytochrome c more reduced. 
This seems to help the cells to avoid the apoptotic effect of MTX leading to the 
development of resistance in human cancer cells.  
In conclusion, we can establish a relationship between cytochrome c redox 
state, apoptosis and development of MTX-resistance in MCF7 breast cancer cells.  
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Annex I 
 
MTT assay protocol (Mosmann, 1983) 
 
Cell viability was assessed by the MTT assay as described by Mosmann 
(1983). MTT assay is based on the ability of viable cells to reduce a tetrazolium salt 
(3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide-MTT) to an 
intercellular purple formazan which can be solubilized and quantified 
spectrophotometrically at the wavelength 570nm. The signal produced is linear to 
the quantity of viable cells. 
 
Solutions: 
MTT solution 0.25% 
Sodium succinate 270µM 
Solubilization reagent: 10% SDS in DMSO and 0.57% acetic acid 
 
Method: 
 
1st Day 
Seed 6x104 cells in a 6 well-plate in 1ml of –GHT medium and leave for an 
overnight period to attach 
 
2nd Day  
Treat the cells with MTX alone or in combination with other compounds: 
 
Compound Pre-incubation period MTX 30nM incubation period  
(alone or in combination) 
5µM TMPD  6 hours 3 days 
300µM Ascorbate 6 hours 6 days 
1µM GSH  2 hours 3 days 
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XX Day 
1. Assess the survival after the MTX incubation period: 
2. Without removing the medium, add 200µl of MTT 0.25% and 700µl of 
270µM sodium succinate solution 
3. Incubate for 2h at 37ºC 
4. After this 2h, remove the MTT + sodium succinate solution and add 1ml of 
the solubilization reagent 
5. Measure the absorbance at 570nm  
6. Express the results as percentage of cell survival relative to control 
(untreated cells) 
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Annex II 
 
Rhodamine 123/IP protocol  
 
A common feature of the early stages of apoptosis is the disruption of active 
mitochondria. Alterations in the mitochondrial membrane are the main event of 
the mitochondrial disruption; this could be due to the formation of transient pores, 
allowing the passage of ions and small molecules. The mitochondrial transient 
permeabilization leads to decoupling of the respiratory chain and cytochrome c 
release into the cytosol. Rhodamine 123 is a cell permeant cationic fluorescent dye 
that is readily taken up by active mitochondria without causing cytotoxicity, 
allowing to identify earlier apoptotic cells, which are not capable of keeping the 
rhodamine 123 inside the mitochondria. In the later stages of apoptosis or in 
necrotic stage, the plasma membrane is disrupted and the cell becomes permeable. 
This permits to label the later apoptotic cells, since the propidium iodide can enter 
into the cell to selectively stain the DNA. 
 
Solutions: 
 
 PBS 1X: 
 PBS 1X + 1% Bovine Serum Albumin (BSA) 
 
Fluorochromes:  
 
Rhodamine 123 1µg/µl – fluorescent emission at 525nm 
Propidium Iodide 5µg/µl – fluorescent emission at 630nm  
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Method 
 
1st Day 
Seed 6x104 cells in a 6 well-plate in 1ml of –GHT medium and leave for an 
overnight period to attach 
 
2nd Day 
Treat the cells with MTX alone or in combination with other compounds: 
 
Compound Pre-incubation 
period 
MTX 50nM;100nM incubation 
period 
(alone or in combination) 
5µM TMPD  12 hours 18 hours 
1mM Ascorbate  12 hours 18 hours 
300nM Staurosporine  18 hours XXX 
Veratridine 30µM 6 hours 18 hours 
1µM GSH  8 hours 18 hours 
1µM GSH + 30µM Veratridine  2 hours + 6 hours 18 hours 
 
Day XX 
1. Without removing the medium, add 5µl of Rhodamine 123 and incubate the 
cells for 30 minutes at 37ºC 
2. Collect the medium and centrifuge at 3500rpm at 4ºC; discard the 
supernatant (SN) – to collect the de-attached cells (dead cells) 
3. Harvest the adherent cells by trypsinization. Centrifuge at 3500 rpm at 4ºC. 
Discard the SN. 
4. Wash with 1ml PBS 1X + 1% BSA.  Centrifuge at 3500 rpm at 4ºC. Discard 
the SN.  
5. Ressuspend the pellet with 500µl PBS 1X + 1% BSA + 0.5µl IP 
6. Analyze the samples by flow cytometry 
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Annex III 
 
 
Preparation of cytosolic extracts 
 
Solutions 
 
Non-denaturant cell lysis buffer: sucrose 250mM, KCl 10mM, HEPES pH 7.4 
20mM, MgCl2 1.5mM, EDTA 0.5mM, EGTA 0.5mM, ultrapure H2O; add immediately 
before use protease cocktail inhibitors 1:100 and PMSF 100mM for a final 
concentration of 1mM 
PBS 1X: 
 
From a 70% confluent 100mm dish: 
 
1. Remove the medium from the cells and wash the cells twice with 2 ml of 
PBS  
2. Remove PBS and add 2ml of PBS to detach the cells using a 
scraper and transfer the cell suspension to a 10ml falcon 
tube.  
3. Wash the plate once again with 3ml PBS and scrape the dish 
to detach the remaining cells  
4. Centrifuge cells at 3500rpm at 4ºC for 10 min 
5. Discard the SN and resuspend cells in 4ml of cold lysis buffer  
6. Vórtex 10s, incubate 5min on ice, vórtex10s again  
7. Homogenize the cells using a Teflon pestle operated at 
730rpm; stroke the cell suspension placed in a glass potter 
20times.  
8. Quantify the total protein by Bradford assay 
9. Use the homogenates immediately to prepare the cytosolic 
extracts 
10. Centrifuge at 3500rpm for 10 min at 4ºC 2 volumes of the 
homogenate prepared before, to pull down the whole cells, 
nuclei and cytoskeleton 
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11. Collect the SN (cytosolic proteins and organelles) and centrifuge it at 
15000rpm for 30min at 4ºC to pull down the organelles 
12. Collect the SN (cytosolic fluid) 
 
Measurement of cytochrome c redox state upon incubation with cytosolic 
extracts 
 
Solutions:  
 Cytochrome c 100µM  
 Cytochrome c 10µM 
 Ascorbate 100mM 
DTT 100mM 
 
Method: 
 
1. Incubate the cytosolic extract with 10µl cytochrome c 100µM for 15min at 
37ºC 
2. Measure the absorbance spectra between wavelengths of 535-550nm 
3. Control for reduction: incubate 10mM of Ascorbate or DTT with 
cytochrome c 10µM 
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Annex IV 
 
Determination of GSH endogenous levels in sensitive and MTX-resistant cells 
 
The following procedure allows the measuring of GSH in-situ as a cell based 
assay using the Glutathione Assay Kit, Fluorimetric (Sigma-Aldrich®).  
 
Solutions: 
 Assay buffer 
 Monochlorobimane Solution (substrate) 
 Lysis buffer 1X 
 Glutathione S-Transferase (40U) 
 Reduced Glutathione 1mM 
 
Method: 
 
1st Day 
Seed 6x104 cells in a 96 well black fluorimeter plate with transparent in 
100µl of –GHT medium and leave for an overnight period to adhere 
 
2nd Day 
1. Remove the medium and wash the cells twice with 200µl PBS 1X 
2. Add 97.5µl of Assay Buffer and 2.5µl of monochlorobimane to each sample 
well and incubate at room temperature in the fluorimeter 
3. At the same time, prepare the standard curve in the same plate as following: 
GSH Standard 1mM Reduced 
Glutathione 
(µl) 
Assay Buffer 
(µl) 
GST Enzyme 
(µl) 
Monochlorobimane 
Solution 
 (µl) 
Blank - 92.5 5 2.5 
1.3nmoles 1.3 91 5 2.5 
2.5nmoles 2.5 90 5 2.5 
5nmoles 5 87.5 5 2.5 
10nmoles 10 82.5 5 2.5 
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4. Measure the fluorescence at 20minutes intervals for 1h 
 
The optimal wavelengths for measuring the fluorescence of the GSH-
Monochlorobimane adduct are: 
 Λexcitation = 390nm 
Λemission    = 478nm 
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Annex V 
  
RT-Real-Time PCR Protocol 
 
Reagents: 
 
RNA Extraction 
 Ultraspec TM RNA Reagent 
 Chlorophorm 
 Ethanol 
 Isopropanol 
 Ethanol 70% Free RNAse 
 DEPC H2O Free RNAse 
 
RT Mix (Vf = 20µl) 
 Buffer 1X: 50mM Tris-HCl pH 8.3, 75mM KCl, 3mM MgCl2 
 DTT 10mM 
 Random Hexamers 125ng/µl 
 dNTPs 500µM each 
 RNAse inhibitor 20U 
 MLV-RT 200U 
 RNA 1µg 
 
Master Mix (Vf = 20µl) 
 Master Mix Buffer 2X 
 SYBR Green 1/1000 
 Primer Forward 1µg/µl 
 Primer Reverse 1µg/µl 
 3µl cDNA product dilution 1/10 
 DEPC H2O  
 
 
 
Annex   Experimental Protocols 
76 
 
Method: 
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From a 70% confluente dish: 
• Extraction using UltraspecTM RNA Reagent and RNAse-free 
chlorophorm 
• Precipitation with isopropanol 
• Wash with ethanol 70% 
• Quantification using Nanodrop 1000 Spectrophotometer 
R
e
v
e
rs
e
 
T
ra
n
sc
ri
p
ti
o
n
 
R
e
a
ct
io
n
 
 
 Incubation of the Reaction Mix (RT) at 37ºC for 1h 
P
C
R
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 Mix the all the reagents of the Master Mix and the specific primers 
for each gene 
 PCR reaction (40 cycles) using StepOnePlusTM detection system: 
- Denaturation 94ºC 1min + 30sec 
- Primer Annealing 59ºC 1min 
- Primer Extension 72ºC 1min 
- Final Extension 72ºC 7min 
G
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 Quantitative ∆∆Ct method 
 Normalization against HPRT each sample 
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Annex VI 
 
Silencing Gene Expression using template PPRHs (de Almagro, 2009) 
 
Brief introduction 
 
Suppression of gene expression constitutes a powerful therapeutical tool to 
inhibit the synthesis of proteins involved in pathological processes. It have been 
developed several types of molecules to decrease gene expression such as mainly 
antisense oligonucleotides (aODNs), small interfering RNAs (siRNAs) and triplex-
forming oligonucleotides (TFOs). However, each of these molecules reveals 
disadvantages such as lack of stability or specificity. To overcome these issues 
hairpins, like Polypurine reverse-Hoogsteen hairpins (PPRHs), and other 
molecules were developed (Ryan, 1998; Sorensen, 2004; Brunet, 2005).  
Hairpins consist of two DNA strands linked by a loop (Giovannangeli, 1991-, 
Kandimalla, 1995; Aviñó, 2001 and 2002), where the DNA strands are linked by 
Watson-Crick (WC) bonds. Hoogsteen bonds are hydrogen bonds between nucleic 
acids, with a different code than WC bonds and this kind of linkage allows the 
formation of triplex structure. This triplex DNA structure is formed when a third 
DNA strand binds to the major groove of double helix via Hoogsteen hydrogen 
bonding (Felsenfeld & Rich, 1957). According to the Hoogsteen geometries, the 
hairpins can be either parallels or antiparallels; antiparallel hairpins bind to 
polypyrimidine stretches in the DNA target sequence, whereas parallel hairpins 
bind to polypurine stretches. The intramolecular linkage of the hairpin is formed 
by reverse hoogsteen bonds, and union with the target sequence is mediated by 
Watson-Crick, d(G#G.C) and d(A#A.T). Accordingly, PPRHs are formed by two 
antiparallel homopurine domains link by a five-thymidine loop (Aviñó, 2002; 
Coma, 2005) and one of the homopurine strands binds with antiparallel 
orientation (by Watson-Crick) to the polypyrimidine target sequence forming a 
triplex. The polypyrimidine stretches, the target of PPRHs are mostly found in 
introns, promoters and with less probability in exons and almost all genes contain 
this type of sequences, implying that PPRHs could be used to target a great number 
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of genes (Almagro, 2009). For this reason, PPRHs may represent a new tool to 
inhibit gene expression in cancer therapy. 
 
Advantages of using PPRHs 
 
 More cytotoxic than aODNs, siRNAs and PPRH structures lacking Hoogsteen 
bonds 
 More stable compared with modified aODNs, without the need for modified 
nucleotides 
 Easy to synthesize and inexpensive, as they are very stable non-modified 
single stranded DNA oligonucleotides, with no special handling 
requirements in contrast to siRNAs 
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Method  
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 Search for the the polypyrimidine stretches in the target sequence to 
design the specific hairpins using: 
www.spi.manderson.org/tfo  (Anderson Cancer Center) 
 BLAST analysis  
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 Seed 6x104 cells in 6-well plate in 1ml of –GHT the night before 
transfection 
 Mix each hairpin with N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium methylsulfate (DOTAP) at appropriate 
oligonucleotide-DOTAP molar ratio 1:100 for 15min at room 
temperature before lipofecting the cells 
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 Cytotoxicity: 
1. After 24h, treat the transfected cells with MTX 30 and 100nM 
2. Assess the viability by MTT assay 3 days later, as described in 
Annex I 
 
 mRNA levels: 
1. Leave the transfected cells for 30h before RNA extraction and 
gene expression quantification. 
2. Determine gene expression  as described in Annex V 
3. Include a scrambled hairpin as a negative control and an 
unrelated gene 
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Annex VII 
 
Development of resistant cell lines MCF7-R Protocol (Selga, 2008) 
 
Treat a semi-confluent 100mm plate of sensitive MCF7 cells with MTX 10-
8M. The cells that survive are left to growing until getting sub-confluent. 70% of 
these cells are treated with 3x10-8M and 30% are maintained at 10-8M until getting 
enough cells to freeze or keep at -80ºC. This procedure is repeated in every 
increment of stepwise concentrations in factors of three until reach to 10-6M of 
MTX, as represented in the scheme below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
10-8M 
MTX 
Sub-
confluent 
30% 
70% 
Sub-
confluent 
Sub-
confluent 
30% 
70% 
3x10-8M 
MTX 10-7M 
MTX 
Store at -80ºC 
… 
… 
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Annex VIII 
 
Oxygen consumption using the Clark type oxygen electrode protocol 
 
 The Hansatech oxygen electrod disc is a Clark type oxygen electrode, also 
known as a polarographic sensor. It is an electrochemical oxygen analyzer based 
on electrochemical reduction of O2 at a negatively charged electrode. This type of 
electrode consists of a silver anode and platinum cathode in contact with an 
electrolyte solution, normally a 50% saturated solution of KCl. The electrode 
section is separated by a semi-permeable membrane, normally Teflon® 
membrane, which is permeable to gases but not reducible ions. Oxygen can pass 
the membrane and reacts with the platinum cathode, becoming reduced. Applying 
a polarizing voltage of 700mV ionizes the electrolyte and initiates current flow. 
The anode provides electrons for the cathode reaction, becoming oxidized. 
 
Anode: Ag  Ag+ + e-  Ag+ + Cl-  AgCl 
 
Cathode: O2 + 2H2O + 2e-  H2O2 + OH  H2O2 + 2e-  2OH- 
 
The reduction of oxygen allows a current to flow creating a potential 
difference which is recorded by computer software. The current flowing is 
proportional to the oxygen concentration giving a signal, thus the trace 
corresponds to oxygen consuming. The solution containing the cells is stirred 
constantly in a closed chamber connected to a water bath at 37ºC. 
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Method 
1. Seed 6x104 cells in a 6 well-plate in 1ml of –GHT medium and leave for an 
overnight period to adhere 
2. Harvest the cells by trypsinization 
3. Centrifuge at 3500 rpm at 4ºC and resuspend the pellet in 1ml pre-warmed 
at 37ºC PBS 1X 
4. Before start to record the oxygen consumption, pre-warm the bath Record 
the oxygen consumption in absence or presence of TMPD 5µM 
5. Determine the steeper slope, representing the oxygen consumption rate 
 
  
 
 
 
